*Communicable Diseases Intelligence*, Year , Volume

Publication date:

<http://health.gov.au/cdi>

COVID-19 Australia: Epidemiology Report 77

Reporting period ending 30 July 2023

COVID-19 Epidemiology and Surveillance Team

# Summary

## Four-week reporting period (3–30 July 2023)

*Case definitions for confirmed and probable cases are in accordance with the coronavirus disease 2019 (COVID-19) Series of National Guidelines for Public Health Units (SoNG).*

**Trends –** Nationally, following the peak of the fifth Omicron wave in the week ending 21 May 2023, there has been a decrease in COVID-19 case notifications. In the four-week period 3–30 July 2023, there were 12,222 confirmed and 13,387 probable cases of COVID-19 reported in Australia to the National Notifiable Diseases Surveillance System (NNDSS). In the most recent reporting fortnight, 11,390 confirmed and probable cases were notified (an average of 814 cases per day), compared with 14,219 in the previous fortnight.

**Age group –** Since late May 2023, notification rates have decreased among all age groups. In the current reporting period, 3–30 July 2023, the highest notification rate was observed among adults aged 90 years and over, whilst the lowest rates were among young people and children aged 19 years or less. For the entire Omicron wave to date (15 December 2021 – 30 July 2023), the highest notification rate has been in adults aged 20 to 29 years.

**Aboriginal and Torres Strait Islander people –** In the reporting period 3–30 July 2023, there were 861 new cases notified in Aboriginal and Torres Strait Islander people. In the Omicron wave to date (15 December 2021 – 30 July 2023), there have been 420,190 cases notified among Aboriginal and Torres Strait Islander people, representing 3.7% of all cases (420,190/11,340,729) during this period.

**Severity –** Since early June 2023, there has been a decrease in the number of cases with severe illness (defined as those admitted to ICU or died). The overall crude case fatality rate from the start of the Omicron wave to date is 0.18%, which is lower than the crude rate during the Delta wave (0.71%). Since the start of the pandemic to 30 July 2023, there have been 185 cases of paediatric inflammatory multisystem syndrome – temporally associated with SARS-CoV-2 (PIMS-TS) reported to the Paediatric Active Enhanced Disease Surveillance network (PAEDS). There was one new case reported in the last four weeks and two new cases from the previous reporting period, giving a total of 19 cases reported since the start of 2023.

**Virology –** For samples collected in the four-week period 3–30 July 2023, all 528 were assigned against Omicron or recombinants consisting of Omicron lineages. This represents a 65% decrease in the number of sequences compared to the previous reporting period. In this reporting period, of the 528 sequences uploaded to AusTrakka during 3–30 July 2023, most (85.2%) were recombinant or recombinant sub-lineages; 14.6% were BA.2.75 sub-sub lineages; one sequence (0.2%) was BA.5 or a BA.5 sub-lineage.

**Acute respiratory illness –** Based on self-reported FluTracking data, there has been an overall increase in the incidence of both ‘fever and cough’ and ‘runny nose and sore throat’ symptoms in the community since late January 2023. Over the current period, the proportion of ‘fever and cough’ has decreased and remains lower than the proportions observed during the same period in 2022. The proportion of ‘runny nose and sore throat’ symptoms has increased in early July 2023, with proportions of this symptom profile now similar to those observed in 2022 for the same period.

**International situation –** According to the World Health Organization (WHO), as of 30 July 2023, over 768 million COVID-19 cases and over 6.9 million deaths have been reported globally since the start of the pandemic, with a global case fatality rate (CFR) of approximately 0.90%. At the WHO regional level, the number of newly reported cases in the four-week period to 30 July 2023 decreased in all regions except the Western Pacific Region (+38%).

Keywords: SARS-CoV-2; novel coronavirus; coronavirus disease 2019; COVID-19; acute respiratory disease; epidemiology; Australia

This reporting period covers the four-week period 3–30 July 2023. Within this period, data for each week is compared. The previous reporting period was the preceding four weeks (5 June – 2 July 2023).1 The focus of this report is on the epidemiological situation in Australia since the beginning of the Omicron wave. For the purposes of this report, 15 December 2021 is used as a proxy for the beginning of this wave. This date was chosen as from this date onward, most sequenced strains from cases were Omicron. Readers are encouraged to consult prior reports in this series for information on the epidemiology of coronavirus disease 2019 (COVID-19) in Australia.

Methods of data analysis in these reports have periodically changed over the course of this reporting series to date. Please refer to the Technical Supplement for details of such changes, and for definitions of terminology.2

From Report #72 onward, and unless specified otherwise, all data from the National Notifiable Diseases Surveillance System (NNDSS) have been extracted using ‘diagnosis date’ rather than ‘notification received date’ (see the Technical Supplement for definitions). Due to COVID-19 reporting changes in several states and territories, the use of ‘diagnosis date’ now provides a more consistent and accurate method for describing transmission trends in Australia.

The case data provided includes both confirmed cases and probable cases reported to the NNDSS, as defined in accordance with the COVID-19 series of national guidelines (SoNG).3 For the purposes of this report, only probable cases from 5 January 2022 are included. Since 1 July 2023, Victoria has ceased collecting and reporting data on probable COVID-19 cases.

From Report #71 onward, population data for Aboriginal and Torres Strait Islander people was updated (from 2016) and is now based on Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) as at 2021. There has been an increase of 185,600 Aboriginal and Torres Strait Islander people (23.2%) since the previous ERP (June 2016). Therefore, notification rate comparisons with reports prior to #71 should be undertaken with caution.

Due to the dynamic nature of data in the NNDSS, numbers may be subject to revision and may vary from numbers previously reported and from case notifications released by states and territories.

# Background and data sources

See the Technical Supplement for general information on COVID-19 including modes of transmission, common symptoms, and severity.2


# Activity

## COVID-19 trends

### *(NNDSS)*

Since the beginning of the pandemic to 30 July 2023, jurisdictions in Australia have reported 11,584,168 COVID-19 notifications to the NNDSS. Following the national peak of the fifth Omicron wave in the week ending 21 May 2023, COVID-19 case notifications have continued to decrease (Figure 1).

****Figure 1: Confirmed and probable weekly COVID-19 notified cases by date of onset, Australia, 29 November 2021 – 30 July 2023 a,b,c****



a Source: NNDSS extract from 16 August 2023 for cases with an illness onset from 29 November 2021 to 30 July 2023.

b Inset graph displays trends from 26 December 2022 to 30 July 2023.

c Since 1 July 2023, Victoria has ceased collecting and reporting data on probable COVID-19 cases.

In the four-week period 3–30 July 2023, there were 12,222 confirmed and 13,387 probable cases of COVID-19 reported in Australia to the NNDSS (Table 1). In the most recent reporting fortnight, a total of 11,390 confirmed and probable cases were notified (an average of 814 cases per day), compared to 14,219 in the previous fortnight (an average of 1,016 cases per day).

****Table 1: Confirmed and probable COVID-19 cases by jurisdiction and date of illness onset, Australia, 15 December 2021 – 30 July 2023 a,b,c****

| Jurisdiction | Reporting period | | | | | Current Omicron wave | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 3–16 July 2023 | | | 17 July–30 July 2023 | | | | 15 December 2021–30 July 2023 | | |
| Confirmed | Probable | Total | Confirmed | Probable | | Total | Confirmed | Probable | Total |
| ACT | 123 (29.2%) | 298 (70.8%) | 421 | 120 (33.9%) | 234 (66.1%) | | 354 | 132,623 (54.6%) | 110,437 (45.4%) | 243,060 |
| NSW | 2,656 (50.9%) | 2,561 (49.1%) | 5,217 | 1,899 (48.6%) | 2,005 (51.4%) | | 3,904 | 2,145,281 (56.2%) | 1,672,590 (43.8%) | 3,817,871 |
| NT | 37 (38.5%) | 59 (61.5%) | 96 | 40 (43.0%) | 53 (57.0%) | | 93 | 24,619 (22.7%) | 83,723 (77.3%) | 108,342 |
| Qld | 1,719 (49.8%) | 1,732 (50.2%) | 3,451 | 1,395 (49.5%) | 1,424 (50.5%) | | 2,819 | 693,542 (40.1%) | 1,036,883 (59.9%) | 1,730,425 |
| SA | 565 (36.1%) | 1,000 (63.9%) | 1,565 | 350 (34.6%) | 662 (65.4%) | | 1,012 | 527,314 (56.6%) | 405,080 (43.4%) | 932,394 |
| Tas. | 104 (15.1%) | 583 (84.9%) | 687 | 90 (21.2%) | 334 (78.8%) | | 424 | 66,527 (22.0%) | 236,333 (78.0%) | 302,860 |
| Vic.d | 988 (99.9%) | 1 (0.1%) | 989 | 1,423 (95.2%) | 72 (4.8%) | | 1,495 | 1,096,699 (38.7%) | 1,737,639 (61.3%) | 2,834,338 |
| WA | 414 (23.1%) | 1,379 (76.9%) | 1,793 | 299 (23.2%) | 990 (76.8%) | | 1,289 | 501,390 (36.6%) | 870,049 (63.4%) | 1,371,439 |
| **Australia** | **6,606 (46.5%)** | **7,613 (53.5%)** | **14,219** | **5,616 (49.3%)** | **5,774 (50.7%)** | | **11,390** | **5,187,995 (45.7%)** | **6,152,734 (54.3%)** | **11,340,729** |

a Source: NNDSS extract from 16 August 2023 for cases with an illness onset from 15 December 2021 to 30 July 2023.

b ACT: Australian Capital Territory; NSW: New South Wales; NT: Northern Territory; Qld: Queensland; SA: South Australia; Tas.: Tasmania; Vic.: Victoria; WA: Western Australia.

c Cases are classified based on jurisdiction of notification not jurisdiction of residence. Some cases are notified to a different jurisdiction than their location of residence.

d Since 1 July 2023, Victoria has ceased collecting and reporting data on probable COVID-19 cases.

As the pandemic has progressed, the proportion of cases reported through surveillance mechanisms has decreased and there are many different sub-lineages of virus circulating simultaneously. Additionally, increases in other measures of disease activity, such as the numbers of people admitted to hospital, intensive care units (ICU) or having died, often lag weeks behind increases in infections in the community. This has made assessing the start of a new wave more complex, with the determination often now only possible several weeks after the wave has commenced.

Since the emergence of the Omicron variant in Australia, there have been five distinct waves of transmission, defined by the predominant Omicron subvariant circulating (Figure 1). The first wave, driven by the BA.1 subvariant, occurred from mid-December 2021 to February 2022, with a peak in cases observed in early January 2022. From March 2022, the BA.2 subvariant was the predominant strain; in this second Omicron wave, there was a primary peak in early April and a secondary peak in late May 2022. In early July 2022, BA.5 (including sub-lineages) became the predominant subvariant detected in Australia, driving a third wave of transmission which peaked in the week ending 24 July 2022. A fourth wave of transmission commenced in late October 2022, driven by a combination of existing and newly emerging Omicron subvariants. This wave peaked during the week ending 11 December 2022. A fifth Omicron wave of transmission, similarly driven by a combination of existing and newly emerging recombinant Omicron subvariants, was signalled by an increasing trend in hospitalisations from mid-March 2023, leading to a peak in notifications in the week ending 21 May 2023 (Figure 1).

Due to a reduction in case ascertainment in all jurisdictions, including changes in testing and reporting requirements, reported case numbers are an underestimate of disease incidence in the community.

## Demographic features

### *(NNDSS)*

Since late May 2023, notification rates have decreased in all age groups (Figure 2). The highest notification rates were in adults aged 60 years and over (Figure 2). In the current reporting period, 3–30 July 2023, the highest notification rate was observed among adults aged 90 years and over, whilst the lowest rates were among young people and children aged 19 years or less (Appendix A, Table A.1). For the entire Omicron wave to date (15 December 2021 – 30 July 2023), the highest notification rate has been in adults aged 20 to 29 years (Appendix A, Table A.1). For this age group, the weekly notification rate peaked in the week ending 9 January 2022 at approximately 5,800 cases per 100,000 population (not shown).

****Figure 2: Confirmed and probable COVID-19 notification rates for ten-year age groups by date of onset, Australia, 26 December 2022 – 30 July 2023 a,b****



a Source: NNDSS extract from 16 August 2023 for cases with an illness onset from 26 December 2022 to 30 July 2023.

b Population data based on Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) as at June 2022.

## Aboriginal and Torres Strait Islander persons

### *(NNDSS)*

Overall, since the start of the pandemic, Aboriginal and Torres Strait Islander status is unknown for approximately 13.0% of COVID-19 notifications in NNDSS. Therefore, the number of cases classified as Aboriginal and Torres Strait Islander people is likely an under-representation. During the reporting period, there were 861 new cases notified among Aboriginal and Torres Strait Islander people (Table 2). In the Omicron wave to date (15 December 2021 – 30 July 2023), notifications among Aboriginal and Torres Strait Islander people have comprised 3.7% of all cases (420,190/11,340,729).

****Table 2: Confirmed and probable cases of COVID-19 among Aboriginal and Torres Strait Islander peoples by jurisdiction and date of onset, Australia, 1 January 2020 – 30 July 2023a,b,c****

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Jurisdiction b | Reporting period 3–30 July 2023 | Omicron to date 15 December 2021 – 30 July 2023 | Delta 16 June – 14 December 2021 | Pandemic to date 1 January 2020 – 30 July 2023 |
| ACT | 16 | 4,278 | 240 | 4,522 |
| NSW | 288 | 138,529 | 7,727 | 146,327 |
| NT | 34 | 26,503 | 94 | 26,598 |
| Qld | 324 | 112,163 | 18 | 112,203 |
| SA | 36 | 23,926 | 3 | 23,934 |
| Tas. | 62 | 17,266 | 1 | 17,279 |
| Vic. | 16 | 36,353 | 1,939 | 38,388 |
| WA | 85 | 61,172 | 0 | 61,174 |
| **Australia** | **861** | **420,190** | **10,022** | **430,425** |

a Source: NNDSS extract from 16 August 2023 for cases with an illness onset from 1 January 2020 to 30 July 2023.

b ACT: Australian Capital Territory; NSW: New South Wales; NT: Northern Territory; Qld: Queensland; SA: South Australia; Tas: Tasmania; Vic: Victoria; WA: Western Australia.

c Cases are classified based on jurisdiction of notification not jurisdiction of residence. Some cases are notified to a different jurisdiction than their location of residence.

Of the COVID-19 cases notified among Aboriginal and Torres Strait Islander people from 15 December 2021 to date, and where location of residence was known, 54.9% (229,060/417,385) lived in a regional or remote area (Table 3). Most cases reported in outer regional and remote areas since the start of the Omicron wave were diagnosed by rapid antigen test (RAT), at 71.5% (55,297/77,380) and 72.4% (37,408/51,644), respectively. It should be noted that the reliance on RATs for diagnosing COVID-19 is greater in regional and remote areas than in major cities, resulting in a larger under-representation of cases in regional and remote areas than in major cities, due to the changes in reporting requirements of positive RATs.

****Table 3: COVID-19 cases among Aboriginal and Torres Strait Islander people by area of remoteness, Australia, 15 December 2021 – 30 July 2023a****

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Jurisdiction b,c | Major city | Inner regional | Outer regional | Remote d |
| ACT | 4,229 | 35 | 12 | 1 |
| NSW | 74,354 | 44,853 | 15,427 | 3,131 |
| NT | 74 | 20 | 8,293 | 17,210 |
| Qld | 43,732 | 25,844 | 31,070 | 11,367 |
| SA | 12,968 | 2,578 | 4,993 | 3,231 |
| Tas. | 206 | 10,542 | 6,078 | 296 |
| Vic. | 20,719 | 11,726 | 3,851 | 19 |
| WA | 32,043 | 4,438 | 7,656 | 16,389 |
| **Australia** | **188,325** | **100,036** | **77,380** | **51,644** |

a Source: NNDSS extract from 16 August 2023 for cases with an illness onset from 15 December 2021 to 30 July 2023. Excludes cases with an overseas place of residence, and where place of residence is unknown.

b ACT: Australian Capital Territory; NSW: New South Wales; NT: Northern Territory; Qld: Queensland; SA: South Australia; Tas.: Tasmania; Vic.: Victoria; WA: Western Australia.

c Cases are classified based on jurisdiction of notification not jurisdiction of residence. Some cases are notified to a different jurisdiction than their location of residence.

d ‘Remote’ here also includes areas classified as ‘very remote’.

Nationally, there have been 416 COVID-19 associated deaths reported in Aboriginal and Torres Strait Islander people from the start of the pandemic to 30 July 2023 (Table 4). This comprises 137 from New South Wales; 126 from Queensland; 57 from the Northern Territory; 53 from Western Australia; 24 from South Australia; 15 from Victoria; and two each from the Australian Capital Territory and Tasmania. Additionally, 681 Aboriginal and Torres Strait Islander cases have been admitted to ICUs nationally. Since the start of the fifth Omicron wave, the notification rate, to NNDSS, of severe cases (measured as those who were admitted to ICU or died) in Aboriginal and Torres Strait Islander people is 10.2 per 100,000 population, compared to 13.2 per 100,000 population during the fourth wave and 19.8 per 100,000 population during the third wave (Table 4). It should be noted that ICU status in NNDSS is likely incomplete.

****Table 4: Age-specific rates of COVID-19 cases by highest level of illness severity (admitted to ICU or died) in Aboriginal and Torres Strait Islander people, Australia, 1 January 2020 to 30 July 2023 a,b****

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Age group (years) | Fifth Omicron wave 1 March – 30 July 2023 | Fourth Omicron wave 24 October 2022 – 28 February 2023 | Third Omicron wave 13 July – 23 October 2022 | Omicron wave to date 15 December 2021 – 30 July 2023 | Pandemic to date 1 January 2020 – 30 July 2023 |
| 0–9 | 0.9 | 3.7 | 5.1 | 19.1 | 20.0 |
| 10–19 | 2.4 | 1.4 | 3.4 | 19.3 | 24.2 |
| 20–29 | 1.8 | 3.0 | 4.2 | 38.7 | 47.8 |
| 30–39 | 1.6 | 8.1 | 9.7 | 45.1 | 60.4 |
| 40–49 | 5.0 | 8.1 | 12.1 | 88.7 | 110.9 |
| 50–59 | 26.2 | 28.5 | 51.3 | 191.4 | 226.7 |
| 60 + | 69.9 | 82.8 | 117.7 | 504.7 | 549.0 |
| **All** | **10.2** | **13.2** | **19.8** | **90.4** | **104.4** |

a ‘ICU’ and ‘died’ are not mutually exclusive categories; ‘died’ can include cases who died with or without prior admission to ICU. Therefore, the number of cases admitted to ICU or having died will not equal the sum of cases in ICU or died.

b Rate per 100,000 population for the given time period. Aboriginal and Torres Strait Islander population data is based on the Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) as at 2021.


## Severity

### *(NNDSS, FluCAN, SPRINT-SARI)*

Given the delay between illness onset and severe illness, and to provide a more accurate assessment of severity, cases with an onset in the last two weeks of the reporting period have been excluded from analyses on severe illness (defined as cases admitted to ICU or died) and on the proportion of cases admitted to ICU or died.

Following the emergence of the Omicron variant, the number of cases with severe illness peaked in mid-January 2022, at over 1,200 severe cases per week (not shown). Since this time there have been subsequent smaller peaks in severe illness, in the week ending 24 July 2022 at 900 severe cases per week and in the week ending 18 December 2022 at close to 500 severe cases per week. Since the start of the fifth Omicron wave, the number of cases with severe illness increased to over 300 severe cases per week in the week ending 28 May 2023 (Figure 3).

****Figure 3: COVID-19 cases, deaths and ICU admissions, Australia, by date of onset, Australia, 27 June 2022 – 30 July 2023 a,b****



a Source: NNDSS extract from 16 August 2023 for cases with an illness onset from 27 June 2022 to 30 July 2023.

b The shaded bars at the right represent the most recent two reporting weeks and should be interpreted with caution, as cases with an illness onset in these weeks may not have yet developed severe disease.

Rates of severe illness were highest in older age groups, particularly those aged 60 years and older (Figure 4). Among this age group, there have been three notable peaks in severe illness since the emergence of Omicron: in the week ending 16 January 2022 (17.3 cases per 100,000 population; not shown), in the week ending 24 July 2022 (13.5 cases per 100,000 population) and in the week ending 18 December 2022 (7.3 cases per 100,000 population). From the start of the fifth Omicron wave to the week ending 30 July 2023, the highest rate of severe illness among those aged 60 years and older was observed in the week ending 28 May 2023 at 4.8 cases per 100,000 population. In comparison, rates of severe illness in younger age groups have remained relatively low and stable throughout the Omicron waves, not surpassing three cases per 100,000 population per week over that period (Figure 4).

****Figure 4: Age-specific rates of COVID-19 cases admitted to ICU or died, by date of onset, Australia, 27 June 2022 to 16 July 2023 a,b,c****

A line graph encompassing the third, fourth and fifth Omicron waves, showing the rates per 100,000 population per week of ICU admission or death, by age group (0–9; 10–19; 20–29; 30–39; 40–49; 50–59; and 60+ years of age). Rates of ICU admission and death have been consistently higher, across this time period, in those aged 60 years and older than in other age groups. The severe-illness peak for the third Omicron wave, in those aged 60 years and older, occurred on the week ending 24 July 2022 with approximately 13.5 cases per 100,000 population per week; the corresponding fourth Omicron wave peak in this age group, on the week ending 18 December 2022, amounted to approximately 7.0 severe-illness cases per 100,000 population per week. An inset graph, covering the same time period, employs a narrower y-axis range and displays the trends for those < 60 years of age. Incidence of severe illness in age groups under 60 years old has been substantially lower, with the 50–59 years age group recording a peak of approximately 1.5 severe-illness cases per 100,000 population per week for the third Omicron wave, on the weeks ending 17 July and 24 July 2022; a lower severe-illness peak for this age group was recorded for the fourth Omicron wave in December 2022, while the severe-illness case rates for those below 50 years of age have remained at or below 0.5 such cases per 100,000 population per week throughout the time period covered by this figure. A peak in the severe-illness case rate, of approximately 4.5 severe-illness cases per 100,000 population per week is evident for those aged 60 years and above in the week ending 28 May 2023.


a Source: NNDSS extract from 16 August 2023 for cases with an illness onset from 27 June 2022 to 16 July 2023; cases with an illness onset in the last two weeks (17–30 July 2023) were excluded to account for the delay between onset and development of severe illness.

b Inset graph displays trends for age groups < 60 years.


c Population data based on Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) as at June 2022.

## Hospitalisation and ICU admissions

### *Influenza Complications Alert Network—FluCAN*

Between 15 December 2021 and 30 July 2023, there were 16,958 hospital admissions with confirmed COVID-19 reported at Influenza Complications Alert Network (FluCAN) sentinel sites, including 5.6% (945/16,958) admitted directly to ICU (Figure 5). During the four-week reporting period (3–30 July 2023), there were 119 hospital admissions with COVID-19 reported at FluCAN sentinel sites, with 5.9% (13/119) admitted directly to ICU.

****Figure 5: Weekly trends for patients admitted with confirmed COVID-19 to FluCAN sentinel hospitals, Australia, 13 December 2021 – 30 July 2023a****



a Source: FluCAN.4

### Short Period Incidence Study of Severe Acute Respiratory Infection—SPRINT-SARI

Between 15 December 2021 and 30 July 2023, there were 5,928 COVID-19 cases admitted to ICUs participating in the sentinel surveillance system Short Period Incidence Study of Severe Acute Respiratory Infection (SPRINT-SARI)5 (Table 5). During this time, 62.0% (3,676/5,928) of patients were discharged home, 13.0% (770/5,928) died in ICU and 5.3% (314/5,928) died within the general hospital ward, with an overall in-hospital mortality rate of 18.3% (1,084/5,928) for COVID-19 cases admitted to ICUs.

****Table 5: Patient outcomes for adult COVID-19 cases (aged greater than or equal to 18 years), Australia, 15 December 2021 – 30 July 2023a****


|  |  |  |
| --- | --- | --- |
| Outcomes | Current reporting period 3–30 July 2023 (n = 85) | Omicron wave to date 15 December 2021 – 30 July 2023 (n = 5,928) |
| **Patient status** |  |  |
| Ongoing care in ICU | 22 (25.9%) | 41 (0.7%) |
| Ongoing care in hospital ward b | 17 (20.0%) | 95 (1.6%) |
| Transfer to other hospital/facility | 0 (0%) | 374 (6.3%) |
| Transfer to rehabilitation | 0 (0%) | 558 (9.4%) |
| Discharged home | 37 (43.5%) | 3,676 (62.0%) |
| Mortality – ICU | 8 (9.4%) | 770 (13.0%) |
| Mortality – hospital ward | 1 (1.2%) | 314 (5.3%) |
| Unknown | 0 (0%) | 76 (1.3%) |
| Missing c | 0 (0%) | 24 (0.4%) |

a Source: SPRINT-SARI.5

b Patients who were admitted in ICU/hospital wards with no discharge information for less than 90 days were assumed to have ongoing care in the hospital.

c Patients who were admitted to ICU/hospital wards for more than 90 days with no discharge information were treated as ‘missing data’.

****Figure 6: Prevalence of comorbidities for COVID-19 cases among admitted adult ICU patients (aged greater than or equal to 18 years), Australia, 3–30 July 2023 a,b****



a Source: SPRINT-SARI. Only includes adult cases (≥ 18 years old) and excludes those with missing data on comorbidities or where comorbidity is unknown.

b Abbreviated comorbidities defined as: Cardiac: chronic cardiac disease; ACEi/ARB: past use of ACE inhibitor or A2 Blocker; CKD: chronic kidney disease; Pulmonary: chronic pulmonary disease (not including asthma); Immune: chronic immunosuppression; and Rheumato: rheumatologic disorder.

In the four-week reporting period (3–30 July 2023), there were 85 adult patients (37 males, 48 females; median age: 63 years; IQR: 46–74 years) with COVID-19 admitted to ICU reported at SPRINT-SARI sentinel sites (Table 5).

Since the start of the Omicron wave (15 December 2021) to 30 July 2023, for patients admitted to SPRINT-SARI sentinel sites with COVID-19 (n = 5,928), the median length of stay in ICU was 3.4 days (range: 0–88.9 days), the median length of stay in hospital was 10.9 days (range: 0.1–89.2 days) and the median duration of mechanical ventilation was 4.1 days (range: < 0.01–82.0 days).

During the four-week reporting period (3–30 July 2023), for patients admitted to SPRINT-SARI sentinel sites with COVID-19 (n = 83), the median length of stay in ICU was 3.4 days (range: 0.5–11.9 days), the median length of stay in hospital was 6.4 days (range: 0.7–21.7 days) and the median duration of mechanical ventilation was 6.1 days (range: 2.1–13.5 days).

### Risk factors for severe disease

Comorbidity data extracted from SPRINT-SARI reflect the sickest patients with COVID-19 who are managed in ICU; data are therefore not generalisable to all cases. In adult patients admitted to ICU with COVID-19 during 3–30 July 2023, where comorbidity information was available, the most prevalent comorbidities were diabetes (24.7%) followed by past use of an angiotensin-converting enzyme (ACE) inhibitor or alpha-2 (A2) blocker (22.4%). Of those adult patients admitted to ICU during the four-week reporting period, for whom comorbidity data was known, 28.2% (24/85) of adult ICU patients had three or more comorbidities.

## Paediatric Inflammatory Multisystem Syndrome – Temporally Associated with SARS-CoV-2

### Paediatric Active Enhanced Disease Surveillance

Since the start of the pandemic to 30 July 2023, there have been 185 cases of paediatric inflammatory multisystem syndrome – temporally associated with SARS-CoV-2 (PIMS-TS) reported to the Paediatric Active Enhanced Disease Surveillance network (PAEDS), with one new case reported in the last four weeks, two new cases from the previous reporting period and a total of 19 cases reported since the start of 2023 (Figure 7). The majority of PIMS-TS cases to date have occurred in those aged 5 to < 12 years (52%; 97/185), followed by those aged 6 months to < 5 years (28%; 51/185). To date, there have been no PIMS-TS associated deaths.

****Figure 7: PIMS-TS cases reported to PAEDS, by sample month and level of care required, Australia, 1 June 2021 – 30 July 2023a****

A stacked-bar chart showing the incidence each month, from June 2021 to July 2023, of cases of paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS). No PIMS-TS cases were reported to PAEDS across June to September 2021, with a broad wave in cases admitted to hospital or ICU across October 2021 to September 2022, constituting at least five cases each month across that time interval (with a minority of such cases ICU-admitted) and peaking at 23 PIMS-TS cases in February 2022. To date, few PIMS-TS cases have been recorded since September 2022, with one case reported in October 2022, none in November, two in December, five in January 2023, two in February, two in March, none in April, three in May, six in June and one in July 2023. No PIMS-TS deaths have yet been reported in Australia. 


a Source: PAEDS.

### COVID-19 deaths

From the start of the fifth Omicron wave (1 March 2023) to the week ending 30 July 2023, there have been 2,840 COVID-19-associated deaths notified. In total, there have been 22,679 COVID-19-associated deaths reported in NNDSS since the start of the pandemic (Table 6). The overall crude case fatality rate from the start of the Omicron wave to date is 0.18%, which is lower than the crude case fatality rate for the Delta wave (0.71%) (Table 7).

****Table 6: Deaths associated with COVID-19 by reporting period, Australia, 1 January 2020 – 30 July 2023 a,b,c****

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Jurisdiction c | Fifth Omicron wave 1 March – 30 July 2023 | Fourth Omicron wave 24 October 2022 – 28 February 2023 | Third Omicron wave 13 July – 23 October 2022 | Omicron wave to date 15 December 2021 – 30 July 2023 | Pandemic to date 1 January 2020 – 30 July 2023 |
| ACT | 37 (1.3%) | 38 (1.0%) | 86 (1.4%) | 252 (1.2%) | 267 (1.2%) |
| NSW | 1,009 (35.5%) | 1,065 (29.1%) | 1,972 (32.2%) | 6,875 (33.7%) | 7,584 (33.4%) |
| NT | 13 (0.5%) | 17 (0.5%) | 22 (0.4%) | 108 (0.5%) | 109 (0.5%) |
| Qld | 477 (16.8%) | 508 (13.9%) | 1,079 (17.6%) | 3,294 (16.2%) | 3,303 (14.6%) |
| SA | 173 (6.1%) | 317 (8.7%) | 495 (8.1%) | 1,572 (7.7%) | 1,577 (7.0%) |
| Tas. | 50 (1.8%) | 63 (1.7%) | 101 (1.6%) | 287 (1.4%) | 304 (1.3%) |
| Vic. | 885 (31.2%) | 1,356 (37.1%) | 2,000 (32.6%) | 6,752 (33.1%) | 8,295 (36.6%) |
| WA | 196 (6.9%) | 290 (7.9%) | 371 (6.1%) | 1,231 (6.0%) | 1,240 (5.5%) |
| **Australia** | **2,840 (100.0%)** | **3,654 (100.0%)** | **6,126 (100.0%)** | **20,371 (100.0%)** | **22,679 (100.0%)** |

a Source: NNDSS, extract from 16 August 2023 for deaths with an illness onset date to 30 July 2023.

b Deaths are categorised into time periods using date of death. Deaths with a missing date of death are classified using date of illness onset.

c ACT: Australian Capital Territory; NSW: New South Wales; NT: Northern Territory; Qld: Queensland; SA: South Australia; Tas.: Tasmania; Vic.: Victoria; WA: Western Australia.

****Table 7: COVID-19 associated case fatality rates among cases notified to NNDSS, by age group and date of onset, 1 January 2020 to 16 July 2023 a,b,c,d****

|  |  |  |  |
| --- | --- | --- | --- |
| Age group (years) | Omicron to date 15 December 2021–18 June 2023 | Delta 16 June–14 December 2021 | Pandemic to date 1 January 2020–18 June 2023 |
| 0–9 | < 0.05% | < 0.05% | < 0.05% |
| 10–19 | < 0.05% | < 0.05% | < 0.05% |
| 20–29 | < 0.05% | < 0.05% | < 0.05% |
| 30–39 | < 0.05% | 0.06% | < 0.05% |
| 40–49 | < 0.05% | 0.18% | < 0.05% |
| 50–59 | < 0.05% | 0.65% | 0.05% |
| 60 + | 1.08% | 6.13% | 1.18% |
| Unknown | < 0.05% | 0.00% | < 0.05% |
| **Australia** | **0.18%** | **0.71%** | **0.20%** |

a Source: NNDSS, extract from 16 August 2023 for deaths with an illness onset date to 16 July 2023.

b To account for the lag between illness onset and the development of severe illness, cases with an onset date in the last two weeks have been excluded from calculations of the case fatality rate.

c A value of 0.00% indicates that no COVID-19 associated fatalities occurred during the indicated period for the specified age group.

d Crude case fatality rates which reflect number of deaths as a proportion of reported COVID-19 cases during specific periods, noting these rates are likely overestimated due to underreporting of cases.

## Genomic surveillance and virology

### (Communicable Disease Genomics Network, AusTrakka and jurisdictional sequencing laboratories)

### Variants of concern (VOC)

AusTrakka6 is actively monitoring and reporting on one lineage and its associated sub- and sub-sub-lineages, currently designated as a variant of concern (VOC) by international organisations, including the World Health Organization (WHO): Omicron (B.1.1.529). The Omicron variant displays a characteristic set of mutations which differentiate the lineage from previously circulating VOCs. Further information on variants and their mutations is available in the Technical Supplement.2

There have been five major sub-lineages defined under B.1.1.529: BA.1, BA.2, BA.3, BA.4 and BA.5, and a large number of sub-lineages, including recombinants, under these; all are designated Omicron. Unlike previous periods in Australia’s COVID-19 waves, where one or two dominant lineages were the main driver of disease, there is currently significant diversity in the range of sub-sub-lineages circulating within Australia. During this reporting period, more than 200 unique lineages have been identified, and it is likely that there are more that are not being characterised through whole genome sequencing. This diversity of circulating lineages has sometimes been referred to as a ‘variant soup’. Many of these circulating lineages will die out without causing a significant disease burden, but others appear to have stronger growth potential.

## Variants of interest and variants under monitoring

The Communicable Diseases Genomics Network (CDGN) VOC working group tracks notable SARS-CoV-2 variants, including:

* two variants of interest (VOI), XBB.1.5 and XBB.1.16; and
* the following variants under monitoring (VUMs) and their descendent lineages: BA.2.75 and BA.2.75.2 (including CH\*), BQ.1 and BQ.1.1\*, and recombinants XBB\* (in particular XBB.1.9.1\* and XBB.1.9.2\*), and XBF\*.

CDGN and this report uses the variants of interest (VOI) classification for lineages with possible evidence for epidemiological, pathological or immunological features of concern. This is consistent with the WHO use of the term.7,8 Variants under monitoring (VUM) are other lineages with early observations of potential significance, but little to no evidence of current concern. In this report, details are included of Omicron subvariants under monitoring as designated by the WHO.

## AusTrakka SARS-CoV-2 genomic epidemiology

From 3 July to 30 July 2023, there were 528 sequences uploaded to AusTrakka, with the most recent collection date of 21 July 2023. This represents a 65% decrease in the number of sequences compared to the previous reporting period. All sequences uploaded during this reporting period have been assigned to sub-lineages within B.1.1.529 (Omicron) or to recombinants consisting of one or more Omicron sub-lineages.

Of the 528 sequences uploaded to AusTrakka between 3 July to 30 July 2023:

* Most (85.2%, 450/528) were recombinant or recombinant sub-lineages;
* 14.6% (77/528) were BA.2 sub-sub lineages; and
* 0.2% (1/528) were BA.5 or BA.5 sub-lineages (Figure 8).

****Figure 8: Omicron sub-lineage in Australia since 1 January 2023 by sample collection date, showing (A) proportions and (B) count per week a,b,c****

Figure 8A plots the proportions of SARS-CoV-2 sequences recorded, by lineage and by date of specimen collection, for each collection week from 1 January 2023 by sample collection date. The figure shows that the dominant sub-lineages sequenced in January–February 2023 were BA.2.75 and the XBF recombinant lineage, with smaller proportions of BA.5, XBB.1.5 and XBC at this time. In subsequent months, the XBF proportion has diminished steadily while that of BA.2.75 has ebbed more gradually, with the largest proportions of sequenced Omicron subvariants identified as XBB.1.5 (March 2023), XBB.1.9.1 (April¬–May 2023), and XBC (June–July 2023).
Figure 8B shows the weekly numbers of SARS-CoV-2 sequences, by lineage and by date of specimen collection, for each collection week from 1 January 2023 by sample collection date. Sequence numbers have dropped progressively across the last ten weeks; while this correlates with the decline in case numbers following the fifth Omicron wave peak in mid-May 2023, it should be noted that sequence numbers are also influenced by testing and referral policies and should therefore not be viewed as a proxy for case numbers. In the current four-week reporting period (3–30 July 2023), the largest numbers of sequences obtained have been those of the XBC and XBB.1.9.1 recombinant lineages, with smaller proportions of XBB.1.16 and BA.2.75.


a Sequences in Austrakka aggregated by epidemiological week.

b The dashed box indicates the distribution of sequences collected within the reporting period.

c Proportions in Figure 8A may not be representative when sequence numbers are small; refer to Figure 8B. Data for earlier epidemiological weeks may change between reporting periods as sequences with older collection dates are uploaded. These numbers are not equivalent to number of cases, as there are many cases which may not be sequenced. Non-VOI and non-VUM Omicron sub-lineages have been collapsed into parent lineages BA.1, BA.2, BA.3, BA.4 and BA.5.

No other BA.1, BA.3 or BA.4 Omicron sub-lineages were identified.

From 1 July 2023, jurisdictional sequencing strategies for SARS-CoV-2 have changed. Some jurisdictions have ceased SARS-CoV-2 sequencing, while other jurisdictions have reduced the number of SARS-CoV-2 cases being sequenced. For jurisdictions which are continuing SARS-CoV-2 genomic surveillance, SARS-CoV-2 cases which are likely to be prioritised for sequencing include ICU or hospitalised cases, high-risk cases, or cases of clinical significance. As a result, these changes are likely to affect the representativeness of the distribution of SARS-CoV-2 sub-lineages across Australia.

Case numbers and sequencing proportion are primarily based on polymerase chain reaction (PCR) results only, as rapid antigen tests (RAT) do not allow for sequencing. Since late 2022, the use of PCR for testing has decreased significantly, as have referrals of positive PCR samples to sequencing laboratories, resulting in changes to sequencing strategies across the country. The Australian SARS-CoV-2 genome sequences in AusTrakka identified as VOCs, VOIs or VUMs are highlighted in Table 8. The VOIs and VUMs where the proportion has increased compared to the previous reporting period are highlighted in yellow, those that have remained stable are highlighted in blue, while those where proportions have decreased are highlighted in green.

The prevalence of the VOI, XBB.1.5, has declined. In the reporting period to 30 July 2023, XBB.1.5 accounted for 4.9% of sequences uploaded to AusTrakka, down from 10.8% in the previous reporting period ending 2 July 2023 (Table 1). In comparison, VOI XBB.1.16 has increased from 23.9% to 30.5% of sequences in the current reporting period. Among the VUMs, the proportions of BA.2.75 sub-lineages (specifically CH.1.1\* sub-sub-lineages) have increased compared to the previous reporting period. Overall, other VUMs (XBB.1.9.1 and XBB.1.9.2 and XBF) have declined or remained stable compared with the previous reporting period. (Table 1).

****Table 8: Australian SARS-CoV-2 genome sequences in AusTrakka, identified as variants of concern, variants of interest or variants under monitoring and proportion of positive cases sequenced for the current and previous reporting periods, and since 23 January 2020 a,b,c,d,e****

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variant category | Measure | Reporting period 3–30 July 2023 | Previous reporting period 5 June – 2 July 2023 | Total sequences to date 23 January 2020 – 30 July 2023 |
| **Variants of concern (VOC)** | BA.1 | 0 (0%) | 0 (%) | 26,251 (17.0%) |
| BA.2 (excluding BA.2.75) | 0 (0%) | 5 (0.3%) | 41,528 (26.8%) |
| BA.2.75 | **77 (14.6%)** | 170 (11.3%) | 13,864 (9.0%) |
| BA.3 | 0 (0%) | 0 (0%) | 3 (< 0.1%) |
| BA.4 | 0 (0%) | 0 (0%) | 5,052 (3.3%) |
| BA.5 | **1 (0.2%)** | 0 (0%) | 43,117 (27.9%) |
| Total recombinants | **450 (85.2%)** | 1,333 (88.4%) | 24,898 (16.1%) |
| **Total VOC** | **528 (100%)** | **1,508 (100%)** | **154,713 (100%)** |
| **Variants of interest (VOI)** | XBB.1.5 + sub-lineages | **26 (4.9%)** | 181 (12.0%) | 5,357 (3.5%) |
| XBB.1.16 | **108 (30.5%)** | 332 (22.1%) | 3,483 (2.2%) |
| **Variants under monitoring (VUM)** | XBB + all sub-lineages | **254 (48.1%)** | 974 (65.0%) | 16,607 (10.76) |
| XBF | **3 (0.57%)** | 9 (0.6%) | 6,549 (4.2%) |
| XBB.1.9.1, XBB.1.9.2 + sub-lineages | **78 (14.8%)** | 303 (20.1%) | 4,876 (3.2%) |
| **Omicron BA.2** | BA.2.75 + sub-lineages | **77 (14.6%)** | 170 (11.3%) | 13,864 (9.0%) |
| CH.1.1 + sub-lineages (BA.2.75.1.1) | **77 (14.6%)** | 169 (11.2%) | 4,221 (2.7%) |

a All lineages have been designated as variants of concern (VOC), variants of interest (VUI) or variants under monitoring (VUM) in Australia, by the CDGN VOC working group.

b Sequencing of samples from cases identified in the reporting period may be in process at the time of reporting. Remaining unsequenced samples may be due to jurisdictional sequencing strategy, or where samples have been deemed unsuitable for sequencing (typically because viral loads were too low for sequencing to be successful).


d Proportional changes compared to the previous 28-day period are highlighted by the following colours: **green boxes indicate a decrease**, **orange boxes indicate** an increase and **blue boxes indicate no change/stable**.

## Acute respiratory illness

### *(FluTracking, ASPREN)*

Based on self-reported FluTracking data,9 there has been an overall increase in the incidence of respiratory illness, ‘fever and cough’ and ‘runny nose and sore throat’ symptoms, in the community since late January 2023. The proportion of ‘fever and cough’ peaked in week ending 4 June 2023 at 2.4% and decreased to a weekly average of 1.4% in the current four-week reporting period and continues to remain lower than the proportion observed during the same period in 2022 (Figure 9). The proportion of ‘runny nose and sore throat’ has continued to increase into early July 2023 and has stabilised during the current four-week reporting period. The proportion of ‘runny nose and sore throat’ is now similar to that observed in 2022 for the same period (Figure 10).

****Figure 9: Weekly trends in fever and cough amongst FluTracking survey participants (age-standardised) compared to the average of the previous five years, Australia, 1 January 2020 – 30 July 2023a****




a In years prior to 2020, FluTracking was activated during the main Influenza season from May to October. A historical average beyond the week ending 11 October is therefore not available. In 2020, FluTracking commenced ten weeks early to capture data for COVID-19.

Over the reporting period, FluTracking data indicated that 12.0% of participants with ‘fever and cough’ were tested for SARS-CoV-2 with a PCR test and 71.0% were tested using a RAT (noting that in some instances RATs will be followed up by a PCR test for the same case). Of those with ‘runny nose and sore throat’, 2.6% were tested for SARS-CoV-2 using a PCR test and 44.9 % were tested using a RAT. In the current reporting period, the percent positivity for ‘fever and cough’ symptoms increased for PCR (12.0%) and decreased for RAT (14.3%) compared to the previous reporting period. For ‘runny nose and sore throat’ symptoms, the percent positivity was similar for PCR (2.6%) and decreased for RAT (2.0%). Note that participants with one set of symptoms are not excluded from having the other. It is important to acknowledge that there may be legitimate reasons why people did not get tested, including barriers to accessing testing. Symptoms reported to FluTracking are not specific to COVID-19 and may also be due to infections with other respiratory pathogens and to chronic diseases, such as asthma.

Since the start of 2023 to 30 July 2023, of those presenting to sentinel ASPREN sites with influenza-like illness who were tested for respiratory viruses, 63.3% (545/861) tested positive for a respiratory virus, a small decrease of 1.6% compared with the previous four-week period. Among those positive, the most common viruses detected were rhinovirus (30.3%; 165/545), followed by influenza A (22.6%; 123/545), influenza B (13.6%; 74/545) and SARS-CoV-2 (12.1%; 66/545).

****Figure 10: Weekly trends in runny nose and sore throat symptoms amongst FluTracking survey participants (age-standardised), Australia, 29 March 2020 – 30 July 2023a****



a Data on runny nose and sore throat were only collected systematically after 29 March 2020, therefore a historical average for this symptom profile is unavailable.

****Table 9: Newly reported and cumulative COVID-19 cases and deaths, by WHO Region, reported in the four-week period to 30 July 2023 a,b****

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| WHO Region | Cumulative cases | New cases reported in the last 4 weeks | Change in new cases in the last 4 weeks b | Cumulative deaths | New deaths reported in the last 4 weeks | Change in new deaths in the last 4 weeks b |
| Western Pacific | 205,521,589 | 850,263 | 38% | 415,436 | 880 | -39% |
| Americas | 193,209,562 | 86,451 | -31% | 2,958,858 | 1,417 | -29% |
| Europe | 275,793,579 | 60,049 | -66% | 2,245,798 | 704 | -75% |
| South-East Asia | 61,197,697 | 6,980 | -61% | 806,588 | 91 | -73% |
| Africa | 9,546,286 | 3,001 | -56% | 175,418 | 14 | -50% |
| Eastern Mediterranean | 23,385,491 | 1,450 | -65% | 351,372 | 26 | -59% |
| **Global** | **768,654,968** | **1,008,194** | **7%** | **6,953,483** | **3,132** | **-53%** |

a Source: World Health Organization Coronavirus (COVID-19) Dashboard,11 accessed 22 August 2023, for data until 30 July 2023.

b Percent change in the number of newly confirmed cases/deaths in the most recent four-week period compared to the four weeks prior.

## COVID-19 trends by WHO region

Current trends in reported COVID-19 cases are an underestimate of the true number of global infections due to the reduction in testing and reporting in many countries. From 7 August 2023, the Regions of the Americas ceased reporting COVID-19 cases and deaths updates to WHO, which will impact the global interpretation. Data presented in this section may be incomplete and should, therefore, be interpreted with caution.

As of 30 July 2023, over 768 million COVID-19 cases and over 6.9 million deaths have been reported globally since the start of the pandemic, with a global case fatality rate (CFR) of approximately 0.90%.10

At the WHO regional level, the number of newly reported cases in the four-week period to 30 July 2023 decreased in all regions except the Western Pacific Region (+38%). The number of newly reported deaths in the four-week period to 30 July 2023 decreased across all regions, with the largest decrease seen in the European Region (-75%) (Table 8).10

# Acknowledgements

We thank public health staff from incident emergency operations centres and public health units in state and territory health departments, and the Australian Government Department of Health and Aged Care, along with state and territory public health laboratories. We thank those who have provided data from surveillance systems, such as Commonwealth respiratory clinics, ASPREN, FluTracking, FluCAN, PAEDS, SPRINT-SARI, the Communicable Disease Genomics Network, AusTrakka and jurisdictional sequencing laboratories.

# Author details

## Corresponding author

COVID-19 Epidemiology and Surveillance Team

Australian Government Department of Health and Aged Care, GPO Box 9484, MDP 14, Canberra, ACT 2601.

Email: epi.coronavirus@health.gov.au

# References

1. COVID-19 National Incident Room Surveillance Team. COVID-19 Australia: Epidemiology Report 76: Reporting period ending 2 July 2023. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.51.
2. COVID-19 National Incident Room Surveillance Team. Technical supplement. COVID-19 Australia: Epidemiology reporting. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.2.
3. Australian Government Department of Health and Aged Care. Coronavirus (COVID-19) – CDNA National Guidelines for Public Health Units. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 14 October 2022. [Accessed on 9 November 2022.] Available from: https://www.health.gov.au/resources/publications/coronavirus-covid-19-cdna-national-guidelines-for-public-health-units.
4. FluCAN (The Influenza Complications Alert Network). FluCAN (Influenza surveillance). [Webpage.] Melbourne: Monash Health, FluCAN. [Accessed on 30 June 2023.] Available from: https://monashhealth.org/services/monash-infectious-diseases/research/influenza-research/flucan-influenza-surveillance-2/.
5. Australian and New Zealand Intensive Care Research Centre (ANZIC-RC). SPRINT-SARI: Short period incidence study of severe acute respiratory infection. [Internet.] Melbourne: Monash University, ANZIC-RC; 2020. Available from: https://www.monash.edu/medicine/sphpm/anzicrc/research/sprint-sari.
6. Communicable Diseases Genomics Network (CDGN). AusTrakka. [Website.] Melbourne: CDGN; 2020. Available from: https://www.cdgn.org.au/austrakka.
7. World Health Organization (WHO). Updated working definitions and primary actions for SARS-CoV-2 variants. Geneva: WHO; 15 March 2023. [Accessed on 16 August 2023.] Available from: https://www.who.int/publications/m/item/updated-working-definitions-and-primary-actions-for--sars-cov-2-variants.
8. WHO. Tracking SARS-CoV-2 variants. [Webpage.] Geneva: WHO; 17 August 2023. [Accessed on 23 August 2023.] Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants.
9. Dalton C, Durrheim D, Fejsa J, Francis L, Carlson S, d’Espaignet ET et al. Flutracking: a weekly Australian community online survey of influenza-like illness in 2006, 2007 and 2008. Commun Dis Intell Q Rep. 2009;33(3):316–22.
10. WHO. Weekly epidemiological update on COVID-19 – 3 August 2023. [Internet.] Geneva: WHO; 3 August 2023. [Accessed on 22 August 2023.] Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---3-august-2023.
11. WHO. WHO Coronavirus Disease (COVID-19) dashboard. [Internet.] Geneva: WHO; 2021. Available from: https://covid19.who.int/.

# Appendix A: Supplementary figures and tables

****Table A.1: COVID-19 cases and rates per 100,000 population, by age group, sex, and date of onset, Australia, 15 December 2021 – 30 July 2023 a,b,c,d****

| Age group (years) | Four-week reporting period | | | | | | Entire ‘Omicron’ wave to date | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 3 July–30 July 2023 | | | | | | 15 December 2021–30 July 2023 | | | | | |
| Cases | | | Rate per 100,000 population | | | Cases | | | Rate per 100,000 population | | |
| Male | Female | Peopled | Male | Female | Peopled | Male | Female | Peopled | Male | Female | Peopled |
| 0–9 | 967 | 865 | 1,865 | 60.2 | 57.1 | 59.8 | 517,435 | 491,442 | 1,129,629 | 32,236.9 | 32,416.3 | 36,192.9 |
| 10–19 | 642 | 653 | 1,319 | 39.3 | 42.4 | 41.6 | 653,118 | 693,939 | 1,483,597 | 40,015.9 | 45,089.3 | 46,783.8 |
| 20–29 | 851 | 1,604 | 2,533 | 48.3 | 95.1 | 73.4 | 791,942 | 967,599 | 1,885,334 | 44,963.6 | 57,341.5 | 54,667.5 |
| 30–39 | 1,203 | 2,203 | 3,498 | 63.9 | 114.9 | 92.1 | 814,658 | 1,016,711 | 1,978,586 | 43,298.2 | 53,016.5 | 52,078.6 |
| 40–49 | 1,212 | 2,110 | 3,396 | 73.8 | 125.5 | 102.2 | 676,322 | 856,872 | 1,655,016 | 41,168.6 | 50,973.5 | 49,792.5 |
| 50–59 | 1,189 | 2,121 | 3,363 | 75.8 | 131.0 | 105.5 | 548,504 | 680,338 | 1,317,002 | 34,986.8 | 42,020.8 | 41,326.8 |
| 60–69 | 1,247 | 1,729 | 3,026 | 92.2 | 119.9 | 108.3 | 397,486 | 460,211 | 911,602 | 29,379.1 | 31,922.1 | 32,619.9 |
| 70–79 | 1,445 | 1,381 | 2,868 | 148.9 | 131.8 | 142.1 | 253,706 | 258,819 | 537,654 | 26,144.9 | 24,702.7 | 26,641.3 |
| 80–89 | 1,119 | 1,294 | 2,442 | 278.0 | 259.8 | 271.2 | 114,668 | 129,971 | 254,384 | 28,492.8 | 26,093.0 | 28,247.5 |
| **90 +** | **437** | **721** | **1,175** | **576.2** | **519.0** | **547.2** | **29,785** | **55,191** | **87,861** | **39,275.5** | **39,732.1** | **40,914.3** |

a Source: NNDSS, extract from 16 August 2023 for notifications to 30 July 2023.

b Population data based on Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) as at June 2022.

c Excludes cases where age was unknown.

d Total cases includes those where sex was unknown and those classified as X, i.e., persons who reported their sex as another term, other than male or female.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Christina Bareja

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk, Meru Sheel and Steph Williams

**Website**: <http://www.health.gov.au/cdi>

**Contacts**CDI is produced by the Office of Health Protection, Australian Government Department of Health and Aged Care, GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2023 Commonwealth of Australia as represented by the Department of Health and Aged Care

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health and Aged Care, GPO Box 9848, Canberra ACT 2601, or via e-mail to: [copyright@health.gov.au](mailto:copyright@health.gov.au)

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.  
<http://www.health.gov.au/cdna>